1314419-66-3

Basic information

• Product Name: (R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine
• Synonyms: (R)-tert-butyl 3-(4-fluorophenoxy)pyrrolidine-1-carboxylate;(R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine
• CAS NO: 1314419-66-3
• Molecular Formula: C15H20FNO3
• Molecular Weight: 281.3226032
• Mol File: 1314419-66-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine(1314419-66-3)
• EPA Substance Registry System: (R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine(1314419-66-3)

Safety Data

• Hazardous Substances Data: 1314419-66-3(Hazardous Substances Data)

Usage

General Description

(R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine is a chemical compound that belongs to the class of pyrrolidine derivatives. It is a chiral compound, with a specific orientation of its molecular structure. The compound has a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom, and a 4-fluorophenoxy group attached to the pyrrolidine ring. (R)-N-Boc-3-(4-fluorophenoxy)pyrrolidine has potential applications in pharmaceutical research, particularly in the development of novel drugs or drug candidates. Its specific chemical structure and properties make it a valuable building block in the synthesis of various biologically active compounds. Further research and studies may explore its pharmacological properties and potential therapeutic applications in various medical conditions.

Upstream product

• 371-41-5 4-Fluorophenol 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 141699-57-2 3-methanesulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1187927-92-9 (S)-3-(4-fluorophenoxy)pyrrolidine 

Relevant articles and documents

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, wherein T, X, Y, U, R1, R2,m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that con